麻豆传媒

Phase III results, now published, should support approval

Liposomal formulation OK for repeat dosing, phase III study indicates

Mechanism different from currently available therapies

Worries about vaccine responsiveness relieved; Big Pharma gets interested

Computer matches live expert in measuring joint space and erosions

More phase II data build case for izokibep

Something to consider when prescribing SGLT-2 inhibitors

Phase II results pave way for bigger and better trial

Placebo-controlled trial gives novel product a tentative boost

AI will revolutionize how healthcare is delivered; how is yet to be determined

Study should help target frequent testing to those most likely to benefit

Secondary trial analysis boosts case for Gazyva

Provocative findings with denosumab, but don't reach for the prescription pad just yet

Novel approach to normalizing immune activity